Jianzheng YANG, Lihua ZOU, Tao YANG, et al. Influencing factors for sarcopenia in type 2 diabetes patients[J]. Journal of Army Medical University, 2023, 45(14): 1562-1568.
DOI:
Jianzheng YANG, Lihua ZOU, Tao YANG, et al. Influencing factors for sarcopenia in type 2 diabetes patients[J]. Journal of Army Medical University, 2023, 45(14): 1562-1568. DOI: 10.16016/j.2097-0927.202303049.
Influencing factors for sarcopenia in type 2 diabetes patients
To explore the demographic and commonly-used laboratory indicators influencing the occurrence of sarcopenia in patients with type 2 diabetes mellitus (T2DM).
Methods
2
A cross-sectional trial was conducted on 69 T2DM patients admitted to our hospital from July 2021 to June 2022. They were divided into case group and control group according to whether they complicated with sarcopenia or not. Their demographic data and laboratory indicators commonly used clinically were collected and compared. The variables with statistically significant differences in the univariate analysis were further included in multivariate logistic regression analysis to explore the influencing factors of the occurrence of sarcopenia in the T2DM patients.
Results
2
Analysis of demographic and common laboratory indicators showed that in the T2DM patients
the older the age
the higher risk of sarcopenia was (
OR
=1.091
95%
CI
: 1.02-1.168
P
=0.011); the lower the body mass index (BMI) value
the higher the risk of sarcopenia was (
OR
=0.691
95%
CI
: 0.538-0.889
P
=0.004); the higher the systolic blood pressure (SBP)
the higher the risk of sarcopenia was (
OR
=1.066
95%
CI
: 1.014-1.121
P
=0.012). White blood cell count
fasting glucose
glycosylated hemoglobin
alanine aminotransferase
aspartate aminotr
ansferase
albumin
uric acid
low-density lipoprotein
high-density lipoprotein
serum calcium
and serum phosphorus had no predictive value for sarcopenia in T2DM patients.
Conclusion
2
In T2DM patients
the demographic factors older age
low BMI and high SBP are associated with occurrence of sarcopenia. But
there has been no evidence of commonly used clinical laboratory indicators having such predictive value.
关键词
Keywords
references
CHEN L K, WOO J, ASSANTACHAI P, et al . Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J ] . J Am Med Dir Assoc, 2020, 21(3): 300-307. e2. DOI: 10.1016/j.jamda.2019.12.012.
ANAGNOSTIS P, GKEKAS N K, ACHILLA C, et al . Type 2 diabetes mellitus is associated with increased risk of sarcopenia: a systematic review and meta-analysis[J ] . Calcif Tissue Int, 2020, 107(5): 453-463. DOI: 10.1007/s00223-020-00742-y.
Chinese guidelines for the prevention and treatment of type 2 diabetes (2020 edition) (Part 1)[J ] . Chin J Pract Intern Med, 2021, 41(8): 668-695. DOI: 10.19538/j.nk2021080106 http://dx.doi.org/10.19538/j.nk2021080106 .
MINETTO M A, BUSSO C, GAMERRO G, et al . Quantitative assessment of volumetric muscle loss: dual-energy X-ray absorptiometry and ultrasonography[J ] . Curr Opin Pharmacol, 2021, 57: 148-156. DOI: 10.1016/j.coph.2021.02.002.
AL-OZAIRI E, ALSAEED D, ALROUDHAN D, et al . Skeletal muscle and metabolic health: how do we increase muscle mass and function in people with type 2 diabetes?[J ] . J Clin Endocrinol Metab, 2021, 106(2): 309-317. DOI: 10.1210/clinem/dgaa835.
ROSENBERG I H. Summary comments[J]. Am J Clin Nutr, 1989, 50(5): 1231-1233. DOI: 10.1093/ajcn/50.5.1231.
GOODPASTER B H, PARK S W, HARRIS T B, et al . The loss of skeletal muscle strength, mass, and quality in older adults: the health, aging and body composition study[J ] . J Gerontol A Biol Sci Med Sci, 2006, 61(10): 1059-1064. DOI: 10.1093/gerona/61.10.1059.
IZZO A, MASSIMINO E, RICCARDI G, et al . A narrative review on sarcopenia in type 2 diabetes mellitus: prevalence and associated factors[J ] . Nutrients, 2021, 13(1): 183. DOI: 10.3390/nu13010183.
IDA S, NAKAI M R, ITO S, et al . Association between sarcopenia and mild cognitive impairment using the Japanese version of the SARC-F in elderly patients with diabetes[J ] . J Am Med Dir Assoc, 2017, 18(9): 809.e9-809.e13. DOI: 10.1016/j.jamda.2017.06.012.
SUGIMOTO K, TABARA Y, IKEGAMI H, et al . Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus[J ] . J Diabetes Investig, 2019, 10(6): 1471-1479. DOI: 10.1111/jdi.13070.
SALTIEL A R. Insulin signaling in health and disease[J]. J Clin Invest, 2021, 131(1): e142241. DOI: 10.1172/JCI142241.
MAIESE K. FoxO transcription factors and regenerative pathways in diabetes mellitus[J]. Curr Neurovasc Res, 2015, 12(4): 404-413. DOI: 10.2174/1567202612666150807112524.
DEFRONZO R A, FERRANNINI E, GROOP L, et al . Type 2 diabetes mellitus[J ] . Nat Rev Dis Primers, 2015, 1: 15019. DOI: 10.1038/nrdp.2015.19.
ATHYROS V G, DOUMAS M, IMPRIALOS K P, et al . Diabetes and lipi d metabolism[J ] . Hormones, 2018, 17(1): 61-67. DOI: 10.1007/s42000-018-0014-8.
PEI J L, WANG B C, WANG D Y. Current studies on molecular mechanisms of insulin resistance[J]. J Diabetes Res, 2022, 2022: 1863429. DOI: 10.1155/2022/1863429.
XU Z Y, YOU W J, CHEN W T, et al . Single-cell RNA sequencing and lipidomics reveal cell and lipid dynamics of fat infiltration in skeletal muscle[J ] . J Cachexia Sarcopenia Muscle, 2021, 12(1): 109-129. DOI: 10.1002/jcsm.12643.
LIGUORI I, RUSSO G, CURCIO F, et al . Oxidative stress, aging, and diseases[J ] . Clin Interv Aging, 2018, 13: 757- 772. DOI: 10.2147/CIA.S158513.
LUC K, SCHRAMM-LUC A, GUZIK T J, et al . Oxidative stress and inflammatory markers in prediabetes and diabetes[J ] . J Physiol Pharmacol, 2019, 70(6). DOI: 10.26402/jpp.2019.6.01.
LEDUC-GAUDET J P, HUSSAIN S N A, BARREIRO E, et al . Mitochondrial dynamics and mitophagy in skeletal muscle health and aging[J ] . Int J Mol Sci, 2021, 22(15): 8179. DOI: 10.3390/ijms22158179.
THIPSAWAT S. Early detection of diabetic nephropathy in patient with type 2 diabetes mellitus: a review of the literature[J]. Diab Vasc Dis Res, 2021, 18(6): 14791641211058856. DOI: 10.1177/14791641211058856.
KAMWA V, WELCH C, HASSAN-SMITH Z. The endocrinology of sarcopenia and frailty[J]. Minerva Endocrinol (Torino), 2021, 46(4): 453-468. DOI: 10.23736/S2724-6507.20.03198-3.
ROBINSON S M, REGINSTER J Y, RIZZOLI R, et al . Does nutrition play a role in the prevention and management of sarcopenia?[J ] . Clin Nutr, 2018, 37(4): 1121-1132. DOI: 10.1016/j.clnu.2017.08.016.
RONG S, WANG L L, PENG Z, et al . The mechanisms and treatments for sarcopenia: could exosomes be a perspective research strategy in the future?[J ] . J Cachexia Sarcopenia Muscle, 2020, 11(2): 348-365. DOI: 10.1002/jcsm.12536.
Predictive value of TyG-BMI, AIP, and postprandial glucose excursion for sarcopenia in patients with type 2 diabetes mellitus
Relative factors to sarcopenia in type 2 diabetes patients
Renal protective effect of equol on type 2 diabetic rats
Correlation of cumulative exposure to metabolic factors with progression of lower extremity arterial disease in type 2 diabetic patients
Epidemiology of major comorbidities in adult patients with osteoarthritis in Beijing from 2015 to 2017
Related Author
CHEN Yue¹
YU Weiwei
GAO Jin
CHEN Xingyu
CHENG Qingfeng
CUI Jian
Cheng CHEN
Qiao ZHANG
Related Institution
Department of Dermatology and Venereology
Department of Endocrinology,Jiangbei Branch/No.9, Hospital of PLA Army, First Affiliated Hospital, Army Medical University (Third Military Medical University)
Department of Endocrinology, the First Affiliated Hospital of Chongqing Medical University
Department of Pain Medicine, First Affiliated Hospital, Army Medical University (Third Military Medical University)